At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Curcumin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
In Brief
A Phase 2 clinical trial evaluating Curcumin, Laboratory Biomarker Analysis, and 1 other intervention for Familial Adenomatous Polyposis. Completed, enrolled 44 participants across 2 sites in 2 countries.
Detailed Summary
This randomized phase II trial studies curcumin in treating patients with familial adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of rectal polyps or colorectal neoplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFamilial Adenomatous Polyposis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartOct 2010
Primary CompletionNov 2016
Study CompletionNov 2016
TodayJul 2026
First PostedMar 24, 2008
Enrollment StartOct 1, 2010
Primary CompletionNov 1, 2016
Study CompletionNov 30, 2016
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 18.3 years ago
Interventions
Curcumindrug
Given PO
Laboratory Biomarker Analysisother
Correlative studies
Placeboother
Given PO